A citation-based method for searching scientific literature

Michael J Pishvaian, Ignacio Garrido-Laguna, Stephen V Liu, Pratik S Multani, Edna Chow-Maneval, Christian Rolfo. JCO Precis Oncol 2018
Times Cited: 5







List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Genomic analyses identify molecular subtypes of pancreatic cancer.
Peter Bailey, David K Chang, Katia Nones, Amber L Johns, Ann-Marie Patch, Marie-Claude Gingras, David K Miller, Angelika N Christ, Tim J C Bruxner, Michael C Quinn,[...]. Nature 2016
40

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Conan G Kinsey, Soledad A Camolotto, Amelie M Boespflug, Katrin P Guillen, Mona Foth, Amanda Truong, Sophia S Schuman, Jill E Shea, Michael T Seipp, Jeffrey T Yap,[...]. Nat Med 2019
310
40

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Daniel D Von Hoff, Thomas Ervin, Francis P Arena, E Gabriela Chiorean, Jeffrey Infante, Malcolm Moore, Thomas Seay, Sergei A Tjulandin, Wen Wee Ma, Mansoor N Saleh,[...]. N Engl J Med 2013
40

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Eric A Collisson, Anguraj Sadanandam, Peter Olson, William J Gibb, Morgan Truitt, Shenda Gu, Janine Cooc, Jennifer Weinkle, Grace E Kim, Lakshmi Jakkula,[...]. Nat Med 2011
971
40

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.
Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E Volmar, S Gabriela Herrera Loeza, Katherine A Hoadley, Naim U Rashid, Lindsay A Williams, Samuel C Eaton, Alexander H Chung,[...]. Nat Genet 2015
907
40

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Thierry Conroy, Françoise Desseigne, Marc Ychou, Olivier Bouché, Rosine Guimbaud, Yves Bécouarn, Antoine Adenis, Jean-Luc Raoul, Sophie Gourgou-Bourgade, Christelle de la Fouchardière,[...]. N Engl J Med 2011
40

Whole genomes redefine the mutational landscape of pancreatic cancer.
Nicola Waddell, Marina Pajic, Ann-Marie Patch, David K Chang, Karin S Kassahn, Peter Bailey, Amber L Johns, David Miller, Katia Nones, Kelly Quek,[...]. Nature 2015
40

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
Andrew J Aguirre, Nabeel Bardeesy, Manisha Sinha, Lyle Lopez, David A Tuveson, James Horner, Mark S Redston, Ronald A DePinho. Genes Dev 2003
744
40

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
40

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.
Justin F Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo-Jack, Luc Friboulet, Jessica J Lin, Harper G Hubbeling, Leila Dardaei, Anna F Farago, Katherine R Schultz,[...]. JCO Precis Oncol 2017
145
40

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
40

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Caroline E McCoach, Anh T Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D Davies, Daniel T Merrick, Paul A Bunn,[...]. Clin Cancer Res 2018
127
40

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Aatur D Singhi, Ben George, Joel R Greenbowe, Jon Chung, James Suh, Anirban Maitra, Samuel J Klempner, Andrew Hendifar, Javle M Milind, Talia Golan,[...]. Gastroenterology 2019
132
40

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
897
40

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
Sunil R Hingorani, Emanuel F Petricoin, Anirban Maitra, Vinodh Rajapakse, Catrina King, Michael A Jacobetz, Sally Ross, Thomas P Conrads, Timothy D Veenstra, Ben A Hitt,[...]. Cancer Cell 2003
40

ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
Florian Guisier, Nicolas Piton, Mathieu Salaun, Luc Thiberville. Clin Lung Cancer 2019
9
40

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
Sunil R Hingorani, Lifu Wang, Asha S Multani, Chelsea Combs, Therese B Deramaudt, Ralph H Hruban, Anil K Rustgi, Sandy Chang, David A Tuveson. Cancer Cell 2005
40

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
176
40

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Monika A Davare, Jacob J Henderson, Anupriya Agarwal, Jacob P Wagner, Sudarshan R Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W Gilheeney, Ana DeCarvalo,[...]. Clin Cancer Res 2018
26
40

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Malcolm J Moore, David Goldstein, John Hamm, Arie Figer, Joel R Hecht, Steven Gallinger, Heather J Au, Pawel Murawa, David Walde, Robert A Wolff,[...]. J Clin Oncol 2007
20

Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
Ken-Ichi Okada, Seiko Hirono, Manabu Kawai, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Masaki Ueno, Shinya Hayami, Hiroki Yamaue. Anticancer Res 2017
35
20

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Alix Portal, Simon Pernot, David Tougeron, Claire Arbaud, Anne Thirot Bidault, Christelle de la Fouchardière, Pascal Hammel, Thierry Lecomte, Johann Dréanic, Romain Coriat,[...]. Br J Cancer 2015
115
20

FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Mashaal Dhir, Mazen S Zenati, Ahmad Hamad, Aatur D Singhi, Nathan Bahary, Melissa E Hogg, Herbert J Zeh, Amer H Zureikat. Ann Surg Oncol 2018
62
20

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, Andrew Dean, Yan-Shen Shan, Gayle Jameson, Teresa Macarulla, Kyung-Hun Lee, David Cunningham, Jean F Blanc,[...]. Lancet 2016
588
20

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
John P Neoptolemos, Malcolm J Moore, Trevor F Cox, Juan W Valle, Daniel H Palmer, Alexander C McDonald, Ross Carter, Niall C Tebbutt, Christos Dervenis, David Smith,[...]. JAMA 2012
364
20

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O'Reilly, David Cunningham, Jonathan Wadsley,[...]. Lancet 2017
981
20

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Thomas J Ettrich, Andreas W Berger, Lukas Perkhofer, Severin Daum, Alexander König, Andreas Dickhut, Uwe Wittel, Kai Wille, Michael Geissler, Hana Algül,[...]. BMC Cancer 2018
41
20

Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.
Matteo Ligorio, Srinjoy Sil, Jose Malagon-Lopez, Linda T Nieman, Sandra Misale, Mauro Di Pilato, Richard Y Ebright, Murat N Karabacak, Anupriya S Kulkarni, Ann Liu,[...]. Cell 2019
244
20

Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Martin Wartenberg, Silvia Cibin, Inti Zlobec, Erik Vassella, Serenella Eppenberger-Castori, Luigi Terracciano, Micha David Eichmann, Mathias Worni, Beat Gloor, Aurel Perren,[...]. Clin Cancer Res 2018
103
20

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
M Haas, J T Siveke, M Schenk, M M Lerch, K Caca, J Freiberg-Richter, L Fischer von Weikersthal, F Kullmann, A Reinacher-Schick, M Fuchs,[...]. Eur J Cancer 2018
17
20

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Helmut Oettle, Peter Neuhaus, Andreas Hochhaus, Jörg Thomas Hartmann, Klaus Gellert, Karsten Ridwelski, Marco Niedergethmann, Carl Zülke, Jörg Fahlke, Michael B Arning,[...]. JAMA 2013
20

Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial.
Yan Shi, Sui Zhang, Quanli Han, Jie Li, Huan Yan, Yao Lv, Huaiyin Shi, Rong Liu, Guanghai Dai. Oncotarget 2017
13
20

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Hideki Ueno, Tatsuya Ioka, Masafumi Ikeda, Shinichi Ohkawa, Hiroaki Yanagimoto, Narikazu Boku, Akira Fukutomi, Kazuya Sugimori, Hideo Baba, Kenji Yamao,[...]. J Clin Oncol 2013
424
20

Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
Quisette P Janssen, Stefan Buettner, Mustafa Suker, Berend R Beumer, Pietro Addeo, Philippe Bachellier, Nathan Bahary, Tanios Bekaii-Saab, Maria A Bali, Marc G Besselink,[...]. J Natl Cancer Inst 2019
134
20

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
Lilian Schwarz, Dewi Vernerey, Jean-Baptiste Bachet, Jean-Jacques Tuech, Fabienne Portales, Pierre Michel, Antonio Sa Cunha. BMC Cancer 2018
54
20

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff,[...]. J Clin Oncol 1997
20

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Sharlene Gill, Yoo-Joung Ko, Christine Cripps, Annie Beaudoin, Sukhbinder Dhesy-Thind, Muhammad Zulfiqar, Pawel Zalewski, Thuan Do, Pablo Cano, Wendy Yin Han Lam,[...]. J Clin Oncol 2016
144
20


Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes.
Carlo Maurer, Sam R Holmstrom, Jing He, Pasquale Laise, Tao Su, Aqeel Ahmed, Hanina Hibshoosh, John A Chabot, Paul E Oberstein, Antonia R Sepulveda,[...]. Gut 2019
79
20

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
Hervé Tiriac, Pascal Belleau, Dannielle D Engle, Dennis Plenker, Astrid Deschênes, Tim D D Somerville, Fieke E M Froeling, Richard A Burkhart, Robert E Denroche, Gun-Ho Jang,[...]. Cancer Discov 2018
415
20

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study.
Alberto Zaniboni, Enrico Aitini, Sandro Barni, Daris Ferrari, Stefano Cascinu, Vincenzo Catalano, Giuseppe Valmadre, Domenica Ferrara, Enzo Veltri, Claudio Codignola,[...]. Cancer Chemother Pharmacol 2012
65
20

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Dietrich A Ruess, Guus J Heynen, Katrin J Ciecielski, Jiaoyu Ai, Alexandra Berninger, Derya Kabacaoglu, Kivanc Görgülü, Zahra Dantes, Sonja M Wörmann, Kalliope N Diakopoulos,[...]. Nat Med 2018
192
20


Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
E Aranda, J L Manzano, F Rivera, M Galán, M Valladares-Ayerbes, C Pericay, M J Safont, M J Mendez, A Irigoyen, A Arrivi,[...]. Ann Oncol 2012
36
20

Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.
Junya Peng, Bao-Fa Sun, Chuan-Yuan Chen, Jia-Yi Zhou, Yu-Sheng Chen, Hao Chen, Lulu Liu, Dan Huang, Jialin Jiang, Guan-Shen Cui,[...]. Cell Res 2019
280
20

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi, Yukiyasu Okamura, Masaru Konishi, Ippei Matsumoto, Yuji Kaneoka, Yasuhiro Shimizu, Shoji Nakamori, Hirohiko Sakamoto,[...]. Lancet 2016
520
20

Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Ali A Mokdad, Rebecca M Minter, Hong Zhu, Mathew M Augustine, Matthew R Porembka, Sam C Wang, Adam C Yopp, John C Mansour, Michael A Choti, Patricio M Polanco. J Clin Oncol 2017
227
20

Clonal evolution driven by superdriver mutations.
Patrick Grossmann, Simona Cristea, Niko Beerenwinkel. BMC Evol Biol 2020
1
100

ROS1 rearrangements define a unique molecular class of lung cancers.
Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang,[...]. J Clin Oncol 2012
20

Recent advances in precision oncology research.
Ann M Bode, Zigang Dong. NPJ Precis Oncol 2018
30
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.